{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:33:11Z","timestamp":1793313191690,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/jcp.0000000000000035","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T12:57:48Z","timestamp":1382360268000},"page":"99-108","source":"Crossref","is-referenced-by-count":15,"title":["Drug Attitude in Adolescents"],"prefix":"10.1097","volume":"34","author":[{"given":"Silvia","family":"Molteni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Comelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Rajendraprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Balottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 7","key":"R1-18-20210128","first-page":"29","article-title":"Use of antipsychotics in children and adolescents.","volume":"66","author":"Findling","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.","volume":"47","author":"Correll","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00023210-200317020-00004","article-title":"Compliance with stimulants for attention-deficithyperactivity disorder: issues and approaches for improvement.","volume":"17","author":"Swanson","year":"2003","journal-title":"CNS Drugs"},{"key":"R5-18-20210128","first-page":"217","article-title":"On the mechanisms of the action of neuroleptic drugs: a theoretical psychodynamic explanation.","volume":"6","author":"Sarwer-Foner","year":"1963","journal-title":"Recent Adv Biol Psychiatry"},{"issue":"9831","key":"R6-18-20210128","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0b013e3181f058a0","article-title":"Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis.","volume":"30","author":"Lambert","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 4","key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.","volume":"70","author":"Velligan","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0447.1994.tb05828.x","article-title":"Subjective response to neuroleptics and the quality of life: implications for treatment outcome.","volume":"380","author":"Awad","year":"1994","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"3","key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2006-941480","article-title":"Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients.","volume":"39","author":"Balestrieri","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/070674378903400716","article-title":"Drug therapy in schizophreniavariability of outcome and prediction of response.","volume":"34","author":"Awad","year":"1989","journal-title":"Can J Psychiatry"},{"issue":"1","key":"R13-18-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1052-z","article-title":"Subjective well-being and quality of life under atypical antipsychotic treatment.","volume":"162","author":"Karow","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.euroneuro.2010.02.001","article-title":"Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST).","volume":"20","author":"Gaebel","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"R15-18-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000144895.75728.2b","article-title":"Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.","volume":"24","author":"Ritsner","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0b013e3182114d21","article-title":"Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models.","volume":"31","author":"Lambert","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"R17-18-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/cap.2005.15.249","article-title":"Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics.","volume":"15","author":"Schimmelmann","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"suppl 3","key":"R18-18-20210128","first-page":"133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.","volume":"10","author":"Naber","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1888-9891(08)72511-4","article-title":"Attitude toward antipsychotic medication as a predictor of antipsychotic treatment discontinuation in first-episode early-onset psychosis.","volume":"1","author":"Fraguas","year":"2008","journal-title":"Rev Psiquiatr Salud Ment"},{"issue":"1","key":"R20-18-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol Med"},{"issue":"12","key":"R21-18-20210128","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1469-7610.2009.02113.x","article-title":"Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory.","volume":"50","author":"Townsend","year":"2009","journal-title":"J Child Psychol Psychiatry"},{"issue":"1","key":"R22-18-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1363461509102292","article-title":"Adolescent experience of psychotropic treatment.","volume":"46","author":"Floersch","year":"2009","journal-title":"Transcult Psychiatry"},{"issue":"2","key":"R23-18-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"suppl 20","key":"R24-18-20210128","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2-3","key":"R26-18-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS).","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"key":"R27-18-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"11","key":"R29-18-20210128","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.1983.01790100074010","article-title":"A childrens global assessment scale (CGAS).","volume":"40","author":"Shaffer","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"R30-18-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQola new facility for the measurement of health-related quality of life.","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"5","key":"R34-18-20210128","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.pnpbp.2005.03.001","article-title":"How antipsychotics work: the patients perspective.","volume":"29","author":"Mizrahi","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"R35-18-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0924-9338(99)00228-X","article-title":"Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology.","volume":"14","author":"Gervin","year":"1999","journal-title":"Eur Psychiatry"},{"issue":"4","key":"R36-18-20210128","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.socscimed.2007.03.047","article-title":"Antipsychotic medication, sedation and mental clouding: an observational study of psychiatric consultations.","volume":"65","author":"Seale","year":"2007","journal-title":"Soc Sci Med"},{"issue":"4","key":"R37-18-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2008-1076729","article-title":"Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.","volume":"41","author":"de Haan","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"R38-18-20210128","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000339092","article-title":"Correlation between early subjective response to antipsychotics and the number of hospitalizations and hospitalization days in a period of 10-11 years in schizophrenia patients.","volume":"66","author":"Murawiec","year":"2012","journal-title":"Neuropsychobiology"},{"issue":"2-3","key":"R39-18-20210128","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.schres.2011.11.008","article-title":"Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.","volume":"134","author":"Yang","year":"2012","journal-title":"Schizophr Res"},{"key":"R40-18-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"7","key":"R41-18-20210128","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4088\/JCP.v65n0709","article-title":"Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.","volume":"65","author":"Hofer","year":"2004","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000000035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:46:04Z","timestamp":1620956764000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201402000-00018"}},"subtitle":["A Key Factor for a Comprehensive Assessment"],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000000035","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}